Skip to main content
. Author manuscript; available in PMC: 2020 Mar 15.
Published in final edited form as: Cancer Res. 2019 Jan 23;79(6):1113–1123. doi: 10.1158/0008-5472.CAN-18-1722

Figure 4. B16.Ecad shows enhanced responses to combination checkpoint blockade.

Figure 4.

(A) Schema of experimental design showing time points of drug dosing. αCTLA4 or Rat Ig (100 μg) was administered on days 4, 7,10,14,16 i.p., αPD-1 or mIgG2b (250 μg) was administered on days 4,6,8,10,12,14,16 i.p. 1×105 tumor cells were injected into the subcutaneous space on the animal’s flank. (B) Kaplan-Meier plot of overall survival; p values, log-rank test. (C-F) Individual tumor outgrowth measured in mm2 once per day (n=5-7 per group). 3/7 B16.Ecad mice remained tumor free 40 days post injection. All other mice developed tumors. (G) Mean tumor size of each treatment group. Data represent mean ±SEM. Statistical analysis by unpaired Student’s t test.